NasdaqCM - Delayed Quote USD

Forte Biosciences, Inc. (FBRX)

Compare
6.73 -0.34 (-4.81%)
At close: 4:00 PM EDT
Loading Chart for FBRX
DELL
  • Previous Close 7.07
  • Open 7.00
  • Bid --
  • Ask --
  • Day's Range 6.60 - 7.18
  • 52 Week Range 6.50 - 21.25
  • Volume 9,697
  • Avg. Volume 5,451
  • Market Cap (intraday) 9.827M
  • Beta (5Y Monthly) 1.45
  • PE Ratio (TTM) --
  • EPS (TTM) -17.25
  • Earnings Date Nov 11, 2024 - Nov 15, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 112.50

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

www.fortebiorx.com

11

Full Time Employees

December 31

Fiscal Year Ends

Recent News: FBRX

View More

Performance Overview: FBRX

Trailing total returns as of 9/18/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

FBRX
67.25%
S&P 500
17.79%

1-Year Return

FBRX
67.17%
S&P 500
26.24%

3-Year Return

FBRX
92.52%
S&P 500
26.74%

5-Year Return

FBRX
97.98%
S&P 500
86.92%

Compare To: FBRX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: FBRX

View More

Valuation Measures

Annual
As of 9/17/2024
  • Market Cap

    10.35M

  • Enterprise Value

    -14.15M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    0.61

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -81.25%

  • Return on Equity (ttm)

    -170.91%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -35.76M

  • Diluted EPS (ttm)

    -17.25

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    24.5M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -18.24M

Research Analysis: FBRX

View More

Company Insights: FBRX

Research Reports: FBRX

View More

People Also Watch